kode immunoeducers

an adjuvant-like initiator of an in situ autologous cancer vaccine

The KIE supplies the immune-initiating signal; the patient's tumour supplies the tumour antigens.

About Kode Immunoeducers: a distinct approach

Kode Immuno-Educers (KIEs) represent a distinct approach to cancer immunotherapy, combining a novel initiating mechanism with established immunological processes to achieve their intended therapeutic effects. KIEs introduce foreign immune-reactive markers (such as the rhamnose epitope presented by K5K) onto tumour-cell membranes, with the aim of recruiting pre-existing antibodies and activating complement.

This is designed to initiate an adjuvant-like immune response and promote the treated tumour as the antigen source for an in situ autologous cancer vaccine. By engaging immune mechanisms also exploited by other therapeutic technologies, KIEs have the potential to act independently and to enhance the effects of other cancer treatments when used in combination.

Kode Biotech Limited owns Kode Technology and licenses it to KodeRx, Kode Agalimmune and Kode Veterinary Sciences.

How a KIE works: the tumour becomes the vaccine

Some vaccines combine a target antigen with an immune-stimulating adjuvant. With KIEs, the patient's tumour provides the antigen source, while the injected KIE supplies an immune-initiating signal.

How K5K works in four steps: 1 administration, injected directly into a tumour; 2 insertion into cell membranes, where its rhamnose head, spacer and lipid tail become embedded in the cell surface; 3 immune recruitment and activation, as pre-existing antibodies bind the rhamnose and activate complement; 4 tumour-cell destruction, the intended effect
Tag, Alarm, Attack: how a KIE is designed to tag tumour cells, recruit immune cells and prompt an immune response
Tag, Alarm, Attack: how a Kode Immunoeducer is designed to work.
KIE mode of action: from the injected tumour, through the lymph node, to an immune response that may extend to distal tumours
KIE mode of action, from the injected tumour to the immune response.
TagThe construct inserts itself into cell membranes within the treated tumour and displays a foreign immune-reactive marker, such as the rhamnose epitope presented by K5K.
AlarmAntibodies the patient already has are intended to bind the marker and activate complement, which may promote local tumour injury and inflammatory signalling.
AttackAntigen-presenting cells may take up tumour material and present the patient's own tumour antigens to T cells. Systemic anti-tumour immunity is the goal, not yet an established clinical effect.

KIEs compared with a vaccine: same principles, new approach

ElementConventional adjuvanted vaccineKIE approach
A — immune activationAn adjuvant included in the vaccine formulation, where required.An injected KIE: a membrane-inserting, antibody-recruiting, complement-activating construct with adjuvant-like activity.
B — target antigenDefined antigens must be identified and are supplied in the product.Tumour-associated antigens and any patient-specific neoantigens already present in the tumour; their identity need not be known.
Where A meets BBoth components are usually delivered together as a formulated vaccine.The KIE construct acts locally in a tumour; injury, antigen release, immune uptake and presentation are intended to occur in situ.
Desired resultAn adaptive immune response to the supplied antigen.An adaptive response to the patient's own tumour antigens, potentially extending beyond the injected lesion.

Not all vaccines contain added adjuvants.

What is distinctive about KIEs: four differences

No predefined antigen payload

The approach does not require identifying and manufacturing a personalised tumour-antigen vaccine for each patient; the tumour itself provides the antigens.

Pre-existing antibodies

The displayed glycan is intended to recruit antibodies already present in the patient, rather than relying solely on generating a new immune response to the drug construct.

The complement system

Complement is one of the most potent components of the innate immune system, contributing to targeted cell destruction, opsonisation, immune-cell recruitment and activation, as well as a range of other immunological functions, including tissue repair and regeneration.

Local start, broader ambition

An accessible tumour lesion provides the starting point for immune activation and systemic anti-tumour immunity.

KIE generations: from natural glycolipids to
Gen 3 KIEs

Each generation of Kode Immunoeducer has improved the same idea: put a marker on the tumour for which naturally occurring antibodies already exist.

Origins

Natural α-Gal glycolipids

Dr Uri Galili showed that α-Gal glycolipids injected into tumours could turn them into targets for the antibodies people already carry.

In 2014 he found that FSL-Galili, Kode Biotech's synthetic version, outperformed the natural glycolipid he was using.

Gen 2 · Kode Agalimmune

AGI-134

A fully synthetic α-Gal KIE, designed to recruit the anti-Gal antibodies people already have and to activate complement.

AGI-134 progressed to a Phase 1/2a human clinical study, with positive clinical findings providing important human experience with the KIE approach. In 38 late-stage, heavily pre-treated patients it met its safety endpoint with no dose-limiting toxicity, and 29% had stable disease, seven of whom had already failed checkpoint-inhibitor immunotherapy.

Preclinical paper: Shaw et al. 2019

Gen 3 · KodeRx and Kode Vet

K5K and Kv9

K5K and Kv9 are Gen 3 KIE molecules, identical by structure. They present rhamnose on a redesigned construct, intended to improve on the Gen 2 KIEs. Details will be published in due course.

Gen 2 and Gen 3 compared

AGI-134 · Gen 2K5K and Kv9 · Gen 3
Marker displayedα-Gal trisaccharideα-Rhamnose monosaccharide
Antibodies recruitedNaturally occurring anti-Gal antibodiesNaturally occurring anti-rhamnose antibodies
Complement activationYes (++)Yes (++++)
Shared aimThe tumour becomes the vaccine. An in situ autologous cancer vaccine: the patient's own tumour supplies the antigens
StagePhase 1/2a safety and dose-finding study completed in 38 late-stage human patientsKv9 in veterinary pilot trials in New Zealand.
K5K is preparing for first-in-human trials

K5K design characteristics: built to reach more patients

K5K is designed from the start to be affordable and practical to deliver, including in health systems with limited resources.

Affordable by design

A target treatment cost of less than US$5,000 per course.

Stable above 40°C

Reducing reliance on refrigeration and cold-chain infrastructure.

Scalable manufacturing

A novel, fully synthetic construct, made by chemical synthesis.

Beyond specialist centres

Potential delivery outside major specialist centres, where clinically appropriate.

How Kode Immunoeducers could be given: the three key routes

Into the tumour

Injected directly into an accessible tumour, or guided by ultrasound or other imaging for deeper tumours.

During surgery

Injected into the tumour or the tumour bed during an operation, without an extra visit.

Outside the body

Tumour cells from a biopsy or surgery, or isolated from blood, can also be modified in the laboratory, as Kode Technology routinely does with cells, and could then be returned to the patient as a vaccine.

Kode Immunoeducers alone or in combination: ideal for combination therapies

As a monotherapy or in combination with other cancer treatments

KIEs have the potential to act independently and to enhance the effects of other cancer treatments when used in combination.

In its first human study, AGI-134, the Gen 2 KIE, met its safety endpoint in 38 late-stage, heavily pre-treated patients. Eleven (29%) had stable disease, seven of them after checkpoint immunotherapy had stopped working, and immune cells entered both injected and uninjected tumours. Side effects were mostly mild to moderate and short-lived; the most common were tiredness and pain at the injection site. Gen 3 KIEs, K5K and Kv9, are designed to build on AGI-134.

KIEs probably best suit earlier-stage disease. The number of doses needed has not yet been determined.

KIE programmes: three programmes

AGI-134

Gen 2 · human oncology

Evidence: Mechanistic preclinical publication (Shaw et al. 2019); Phase 1/2a safety and dose-finding study completed in 38 late-stage human patients, with stable disease in 29%.

Kv9

Gen 3 · veterinary oncology

Evidence: Preliminary canine experience provides translational evidence.

K5K

Gen 3 · human oncology

Evidence: Strong laboratory data.
Investigational human-development candidate; safety and efficacy have not yet been established in humans.

K5K and Kv9 are Gen 3 KIE molecules, identical by structure.
Blood cancers are a future direction, not yet a programme.

timeline

Kv9: what dogs can tell us

Kv9 is an experimental Gen 3 KIE licensed to Kode Veterinary Sciences, and is being evaluated in veterinary oncology across multiple solid tumour types, with preliminary anti-tumour responses observed.

Why dogs are a good model for humans

Pet dogs develop cancers naturally, as people do. The US National Cancer Institute lists the advantages: similar body size, a shared home environment, an intact immune system, tumours that grow naturally with their surrounding tissue, and the same kinds of treatment as people. An intact immune system matters most for an immunotherapy.

NCI Comparative Oncology Program

Tumour types in the New Zealand veterinary pilot study

  • Soft tissue sarcomas
  • Mast cell tumours
  • Mammary gland tumours
  • Melanomas
  • Anal gland tumours
  • Squamous cell carcinomas
  • Other tumours may be considered
Kode Vet clinical trial

What the trials are assessing

The safety and efficacy of Kv9 across a range of solid tumours, in pet dogs, cats and horses treated under veterinary supervision. Preliminary canine experience provides translational evidence.

Visit Kode Veterinary Sciences →

Kv9 is experimental and has not been approved by any regulator.
The veterinary pilot trials run under veterinary supervision; taking part is voluntary and does not guarantee any outcome.

K5K development path: six steps, in order

K5K builds on more than three decades of scientific research and clinical and translational experience with Kode Immunoeducers. It is preparing to progress to first-in-human clinical trials once funding is secured; the next stage is establishing its safety, tolerability and biological activity in people with cancer.

K5K's development path

  1. PreclinicalLaboratory and animal evidence of safety and potential efficacy, including toxicology
  2. Trial approvalIs it safe enough to test in people? (Regulator and ethics approval)
  3. Phase 0First in human: a very small dose in a few patients, to check how it behaves in the body
  4. Phase 1/2aIs the dosing regime safe, and are there signs of anti-tumour activity?
  5. Phase 2bDoes it control tumours, including ones not injected, in a chosen cancer type?
  6. Phase 3Does a randomised trial against standard care confirm the benefit?

KIE commercialisation partners

KIE partnerships go through the Kode Group companies that own each programme: KodeRx and Kode Agalimmune for human cancer, and Kode Veterinary Sciences for veterinary cancer.

Human cancer · K5K

Licensing and partnering for K5K.

Get in touch

Human cancer · AGI-134

Licensing and partnering for AGI-134.

Get in touch

Equitable Oncology, an independently governed NZ charity (CC64930), coordinates the clinical, scientific and philanthropic partnerships to advance K5K and AGI-134.

Partner with Equitable Oncology ↗

Veterinary cancer · Kv9

Developing and commercialising Kv9.

Get in touch

Kode Immunoeducers: frequently asked questions

What is a Kode Immunoeducer (KIE)?

A membrane-inserting, antibody-recruiting, complement-activating construct with adjuvant-like activity, designed to use the patient's own tumour as the antigen source for in situ vaccination.

How is a KIE different from a personalised cancer vaccine?

A personalised vaccine needs the patient's tumour antigens to be identified and manufactured. With a KIE, the tumour itself provides the antigens, which need not be identified in advance.

What does "in situ autologous cancer vaccine" mean?

The vaccine effect is intended to happen inside the patient's own tumour (in situ), using the patient's own tumour antigens (autologous), rather than antigens supplied in a vial.

What role do pre-existing antibodies and complement play?

The marker a KIE displays is intended to recruit antibodies the patient already has and to activate complement, which may promote local tumour injury, inflammatory signalling and uptake of tumour material by antigen-presenting cells.

What are AGI-134, K5K and Kv9, and what stage is each at?

AGI-134 is a Gen 2 KIE that has completed a Phase 1/2a safety and dose-finding study in 38 late-stage human patients, with stable disease in 29% of them. K5K is an investigational Gen 3 KIE in human development. Kv9, also a Gen 3 KIE, is in veterinary development; preliminary canine experience is translational evidence only. All are investigational.

Why are there generations of KIEs?

Each generation refines the design. AGI-134 (Gen 2 KIE) presents α-Gal and relies on the antibodies a patient already has. K5K and Kv9 (Gen 3 KIEs) present rhamnose on a redesigned construct, intended to improve on the Gen 2 KIEs. Details will be published in due course.

more questions in the FAQ

Work with us: partner on Kode Immunoeducers

Licensing and commercial partnerships in human cancer go through KodeRx or Kode Agalimmune; veterinary cancer through Kode Veterinary Sciences. Partner with Equitable Oncology to help bring these investigational therapies to patients and make them accessible worldwide. Everything else starts with Kode Biotech.